Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 2, 2025

Global and China Automotive Lighting and Ambient light System Research Report 2025 Featuring 8 International Suppliers, 10 Chinese Suppliers and Intelligent Lighting Application Cases of 13 OEMs

View original at globenewswire.com
Global and China Automotive Lighting and Ambient light System Research Report 2025 Featuring 8 International Suppliers, 10 Chinese Suppliers and Intelligent Lighting Application Cases of 13 OEMs Dublin, Dec…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • LED low beam lights were installed in 9.412 million vehicles in H1 2025, with an installation rate of 89.1%, up by 9.9% on a like-on-like basis

    80% confidence
  • In H1 2025 ADAS indicator lights were installed in 755,000 vehicles, with an installation rate of 7.1%, a year-on-year jump of 1098%

    80% confidence
  • In H1 2025, BYD's installation rate of small blue lights soared to 65.4%

    80% confidence
  • China's automotive LED lighting market will be worth around RMB61.87 billion in 2025, projected to increase to RMB82.79 billion in 2030

    80% confidence
  • China's automotive lighting market will be valued at about RMB65.12 billion in 2025, projected to reach RMB88.22 billion in 2030

    80% confidence
  • China's automotive LED lighting market will be worth RMB 80 billion in 2030

    80% confidence
  • The installation rate of automotive LED lighting approached 90% in 2025H1

    80% confidence
  • LED high beam lights were installed in 9.407 million vehicles in H1 2025, with an installation rate of 89.1%, 10.0% higher than the same period of the previous year

    80% confidence
  • Automotive ambient lighting has evolved from single ambient decoration function into combination of auxiliary lighting and scenario-based interactive functions, becoming new intelligent cockpit element

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com